PREFACE: Introductory RemarksCHAPTER 1: Dystonia: Abnormal Movements Result from Loss of InhibitionCHAPTER 2: Sensory Deficits in Dystonia and Their SignificanceCHAPTER 3: Focal Hand Dystonia May Result from Aberrant NeuoplasticityCHAPTER 4: Basal Ganglia Neuronal Discharge in Primary and Secondary DystoniaCHAPTER 5: Distribution of Impairment of Cortical Inhibitory Mechanisms in Focal Dystonia: A Study of Silent Period Evoked by Transcranial Magnetic StimulationCHAPTER 6: Lasting Supression of the Premotor Cortical Overactivity in Arm Dystonia.CHAPTER 7: Biochemistry of Oppenheim's DystoniaCHAPTER 8: Biochemistry of TorsinA and AAA+ ProteinsCHAPTER 9: Distribution of TorsinA in the Developmental and Adult Rat BrainCHAPTER 10: Animal ModelsCHAPTER 11: A Transgenic Mouse Model for DYT1 DystoniaCHAPTER 12: Dominant TorsinA Mutations in Cellular SystemsCHAPTER 13: In vivo Suppression of Protein Aggregation by a C. elegans Torsin HomologueCHAPTER 14: TorsinA in PC12 Cells: Localization in the Endoplasmic Reticulum and Response to StressCHAPTER 15: An Epidemiological Survey of Dystonia (ESD) within the Entire Population of Northeast England Over the Last 9 YearsCHAPTER 16: Genetics of Torsin Dystonia: Classification and Clinical FeaturesCHAPTER 17: Genetics of DYT 6, 7, and 12CHAPTER 18: Myoclonus-dystonia SyndromeCHAPTER 19: Non-dystonic Features of DystoniaCHAPTER 20: DYT5 (Dopa-Responsive Dystonia)CHAPTER 21: DYT3 (lubag)CHAPTER 22: Two Forms of Focal Dystonia are Associated with Polymorphisms in the Dopamine 5 Receptor GeneCHAPTER 23: Evaluation of GRIK5 (KA2) as a Candidate Gene for Rapid-Onset Dystonia-Parkinsonism (RDP, DYT12)CHAPTER 24: Abnormalities of Brain Function in Non-manifesting DYT1 CarriersCHAPTER 25: Dysfunction of Dopaminergic Pathways in DystoniaCHAPTER 26: Functional Anatomy and Pharmacology of Animal Models of DystoniaCHAPTER 27: Sporadic and Familial Primary Torsion Dystonia (PTD) Cases in ItalyCHAPTER 28: Development of a Cell-based Assay to Screen Compounds for Resolution of Mutant TorsinA AggregatesCHAPTER 29: Cognition and Affect in Patients with Cervical Dystonia and TremorCHAPTER 30: Clinical Features of the Geste Antagoniste in Cervical DystoniaCHAPTER 31: Cognitive Executive Function in Idiopathic DystoniaCHAPTER 32: Analysis of the Duration of Botulinum Toxin Type B (Myobloc) in Patients with Cervical DystoniaCHAPTER 33: Is Phenotypic Variation of Hereditary Progressive Dystonia with Marked Diurnal Fluctuation/Dopa-responsive Dystonia (HPD/DRD) Caused by Difference of the Locus of Mutation on the GTP Cyclohydorolase 1 (GCH-1) Gene?CHAPTER 34: Focal Task-Specific Dystonia in Musicians: Historical Background and PhenomenologyCHAPTER 35: Brain Mapping in Musician's DystoniaCHAPTER 36: Therapy of Muscian's DystoniaCHAPTER 37: Immobilization Treatment of Focal DystoniaCHAPTER 38: A Review of 111 Musicians with Focal Dystonia Seen at a Performing Artist's Clinic 1985-2002CHAPTER 39: The Impact of Focal Dystonia on the Working Life of Musicians Within the UKCHAPTER 40: Focal Dystonia in Violin and Viola InstrumentalistsCHAPTER 41: Abnormal Sensorimotor Processing of Pianists with Focal DystoniaCHAPTER 42: Medical Therapy and Botulinum ToxinCHAPTER 43: Pallidotomy for DystoniaCHAPTER 44: Pallidal Stimulation for DystoniaCHAPTER 45: Surgery on Dystonia Leading to a Circuit ModelCHAPTER 46: Off-period Dystonia in Parkinson's Disease but not Secondary and Primary Generalized Dystonia is Improved by High Frequency Stimulation of the Subthalamic NucleusCHAPTER 47: Autonomic Side Effects of Botulinum Toxin Type B TherapyCHAPTER 48: Dystonia and Headaches: The Response to Botulinum Toxin (BTx) TherapyCHAPTER 49: Inter-rater Agreement for the Ancillary Non-Motor Rating Scales Included in the Unified Dystonia Rating Scale (UDRS) and the Burke-Fahn-Marsden (BFM) Rating Scale for Dystonia.